Skip to main content
    J

    Jupiter Neurosciences, Inc. Common Stock (JUNS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.54
    -0.16 (-9.41%)

    Market Cap: $2.24M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Jupiter Neurosciences, Inc. Common Stock (JUNS) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Jupiter Neurosciences, Inc. Common Stock (JUNS) has a market cap of $2.24M and an enterprise value of $2.17M. It kept -17976.04% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 3.34% below the market cap, as cash exceeds debt.

    Market Cap$2.24M
    Enterprise Value$2.17M
    Latest price (Nov 17, 2026)$1.54

    Key Dates

    Last Earnings DateAug 14, 2026
    Fiscal Year EndDecember

    Valuation Ratios

    The price to sales ratio is 19.1x.

    P/S Ratio19.1x
    Forward P/S0.2x

    Price Statistics

    The stock is down 98.47% over 52 weeks and trades 41.67% below its 50-day average.

    Beta (1Y)1.61
    52-Week Change-98.47%
    1-Month Change-44.00%
    3-Month Change-67.92%
    6-Month Change-93.58%
    Total Return (1Y)-98.47%
    Return vs SPY (1Y)-109.92%
    Max Drawdown (1Y)-98.42%
    Sharpe Ratio (1Y)-3.29
    Correlation with SPY (1Y)0.18
    50-Day Average$2.64
    200-Day Average$17.16
    52-Week Range$1.63 to $101.25
    RSI (14 Days)28.2
    Average Volume (20 Days)19.08K

    Financial Position

    Current assets cover 0.49x current liabilities.

    Current Ratio0.49x
    Quick Ratio0.44x
    Interest Coverage-30.10x

    Returns and Efficiency

    Return on invested capital is 1154.48% over the last 12 months.

    Return on Assets (ROA)-870.87%
    Return on Invested Capital (ROIC)1154.48%
    Asset Turnover0.04x
    Inventory Turnover0.12x
    Receivables Turnover15.36x
    Cash Conversion Cycle-15806 days

    Scores

    JUNS has an Altman Z-Score of -68.30, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score-68.30
    Altman Z ZoneDistress
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $78.64K over the last 12 months.

    Revenue$78.64K
    Gross Profit$62.53K
    Operating Income-$13.31M
    Pretax Income-$14.14M
    Net Income-$14.14M
    EBITDA-$12.92M
    EBIT-$13.68M
    Reported EPS (TTM)-$9.59

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$300.62K
    Total Debt$225.69K
    Net Cash$74.94K
    Net Cash Per Share$0.08
    Working Capital-$1.33M
    Shareholder Equity-$1.16M
    Total Assets$1.62M
    Total Liabilities$2.79M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$8.82M
    FCF Per Share-$6.69
    Depreciation and Amortization$766.67K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -16926.86%.

    Gross Margin79.52%
    Operating Margin-16926.86%
    Pretax Margin-17976.04%
    Net Margin-17976.04%
    EBITDA Margin-16425.69%
    EBIT Margin-17400.66%

    Growth

    Revenue fell 54.62% a year over 3 years.

    Revenue Growth (3Y CAGR)-54.62%
    Revenue Growth (5Y CAGR)-54.57%

    Revenue and profit by year

    Dividends and Yields

    JUNS does not pay a dividend.

    Buyback Yield-124.42%
    Shareholder Yield-124.42%

    Stock Splits

    The last split was a 1-for-75 reverse split on Aug 7, 2026.

    Last Split DateAug 7, 2026
    Split TypeReverse split
    Split Ratio1:75

    Peer Position

    Against 3 similar companies, JUNS has the 2nd highest P/S.

    P/S Ratio19.1x vs 2.8x median
    ROIC1154.48% vs -90.21% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 52235.29% a year over the next fiscal year.

    Revenue Growth Forecast (1Y CAGR)+52235.29%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About JUNS

    What is JUNS's market cap?

    Jupiter Neurosciences, Inc. Common Stock has a market cap of $2.24M. Its enterprise value, which adds debt and subtracts cash, is $2.17M.

    How many shares of JUNS are outstanding?

    Jupiter Neurosciences, Inc. Common Stock has 973.63K shares outstanding.

    Does JUNS pay a dividend?

    No. Jupiter Neurosciences, Inc. Common Stock does not pay a dividend.

    How much debt does JUNS have?

    Jupiter Neurosciences, Inc. Common Stock has $225.69K of total debt and $300.62K of cash and equivalents, a net cash position of $74.94K.